PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-sta… Read more
PROQR THERAPEUTICS EO-04 (0PQ) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PROQR THERAPEUTICS EO-04 (0PQ) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PROQR THERAPEUTICS EO-04 - Net Assets Trend (None–None)
This chart illustrates how PROQR THERAPEUTICS EO-04's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PROQR THERAPEUTICS EO-04 (None–None)
The table below shows the annual net assets of PROQR THERAPEUTICS EO-04 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PROQR THERAPEUTICS EO-04's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PROQR THERAPEUTICS EO-04 Competitors by Market Cap
The table below lists competitors of PROQR THERAPEUTICS EO-04 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Impact Develop
RO:IMP
|
$99.80 Million |
|
Aftermath Silver Ltd
OTCQX:AAGFF
|
$99.81 Million |
|
Generation Mining Ltd
TO:GENM
|
$99.82 Million |
|
Bauer AG
HM:B5A
|
$99.82 Million |
|
K.P. Energy Limited
NSE:KPEL
|
$99.75 Million |
|
Shandong Molong Petroleum Machinery Company Limited
PINK:SHANY
|
$99.73 Million |
|
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
|
$99.73 Million |
|
Orthocell Ltd
AU:OCC
|
$99.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PROQR THERAPEUTICS EO-04's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PROQR THERAPEUTICS EO-04's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PROQR THERAPEUTICS EO-04 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PROQR THERAPEUTICS EO-04's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PROQR THERAPEUTICS EO-04 (0PQ) | €- | N/A | N/A | $99.77 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |